@article{297a914092b34c6f92b288f27cc633c7,
title = "Circulating Tumor DNA as a Prognostic Marker in Stage III Colon Cancer - Reply",
author = "Jeanne Tie and Bert Vogelstein and Peter Gibbs",
note = "Funding Information: Conflict of Interest Disclosures: Dr Vogelstein reported receiving grants from Ludwig Cancer Research, the Marcus Foundation, the Lustgarten Foundation, and Howard Hughes Medical Institute; holding equity in Thrive Earlier Detection, Personal Genome Diagnostics, Cage Pharma, NeoPhore, Nexus, and PhoreMost; receiving personal fees from Eisai-Morphotek and Sysmex Inostics; having patents pending, issued, licensed, and with royalties paid for Safe-SeqS and Optimization of Methods for Detecting Rare Mutations in Clinical; and serving as a founder of Personal Genome Diagnostics and Thrive Earlier Detection and a paid adviser to Thrive Earlier Detection, Sysmex Inostics, Eisai-Morphotek, Cage Pharma, NeoPhore, PhoreMost, and Nexus, with licenses associated with equity or royalty payments personally and to Johns Hopkins University. No other disclosures were reported. ",
year = "2020",
month = jun,
doi = "10.1001/jamaoncol.2020.0289",
language = "English (US)",
volume = "6",
pages = "932--933",
journal = "JAMA Oncology",
issn = "2374-2437",
publisher = "American Medical Association",
number = "6",
}